Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Computer model may help tailor blood pressure meds for liver patients

NCT ID NCT07397481

Disease control Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a computer program (Simcyp) could predict the right doses of two blood pressure drugs, nebivolol and carvedilol, for people with liver cirrhosis and high blood pressure. Forty patients were randomly assigned to one of the two drugs and monitored for three months. Researchers measured blood pressure, liver blood flow, and side effects to see if the computer-guided doses worked well in real life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nebivolol and carvedilol (blood pressure medications)
What this could lead to
If successful, this approach could help doctors choose safer, more effective doses of blood pressure drugs for patients with liver cirrhosis.
What could go wrong
This is a small, early pilot study with only 40 patients, so results may not apply to everyone. The computer predictions need more testing before routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Mar 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age of patients \> 18 years. * Diagnosed with cirrhosis * Have cardiovascular disease(Hypertension ) * Presence of portal hypertension * No history of variceal bleeding Exclusion Criteria: * Patients with kidney disorder or dialysis * Hypersensitivity to study medications * Active cancer history in the last 2 years * Taking drugs that interact with antihypertensive drugs in the last two weeks * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver essential hypertension hypertensive disorder portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial hypertension Liver cirrhosis

Contacts and locations

Locations

  • Kafrelsheikh University

    Cairo, Egypt, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.